Newport Beach, CANCT07213791Now EnrollingIRB Ready

Ovarian Neoplasms Clinical Trial in Newport Beach, CA

Access cutting-edge ovarian neoplasms treatment through this clinical trial at a research site in Newport Beach. Study-provided care at no cost to qualified participants.

Sponsored by Eli Lilly and Company

Quick Self-Assessment

See if you qualify for this Newport Beach location

Preparing your pre-screening questions…

Expert Care in Newport Beach

Access ovarian neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ovarian neoplasms treatment provided free

Apply for This Newport Beach Location

Check if you qualify for this ovarian neoplasms clinical trial in Newport Beach, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Newport Beach

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Newport Beach site if eligible
  4. 4Begin participation

About This Ovarian Neoplasms Study in Newport Beach

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.

Sponsor: Eli Lilly and Company

Who Can Participate

Inclusion Criteria

Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment
Must have histologically or cytologically confirmed diagnosis of one of the following:
Adenocarcinoma of the pancreas
Hormone receptor (HR)-positive human epidermal growth factor 2 (HER2)-negative breast cancer
HER2-positive breast cancer
Triple negative breast cancer (TNBC)
Platinum-resistant or refractory ovarian cancer (including ovarian carcinosarcoma)
Other solid tumors
Gastric cancer (adenocarcinoma)
Colorectal cancer (CRC)
Esophageal cancer (squamous cell carcinoma or adenocarcinoma)
Cholangiocarcinoma
Must have received prior treatments as indicated below:
Adenocarcinoma of the pancreas: Participants must have received at least 1, but no more than 2 prior regimens for locally advanced unresectable or metastatic disease.
HR-positive HER2-negative breast cancer: Participants must have received less than or equal to (≤)5 prior lines of treatment for advanced or metastatic disease, which must include a cyclin-dependent kinase 4/6 inhibitor.
HER2-positive breast cancer: Participants must have received at least 2 lines of HER2-targeted therapy, which should include at least 1 antibody-drug conjugate (ADC) for metastatic disease (if locally available).
TNBC: Participants must have received at least 2 lines of therapy for metastatic disease.
Platinum-resistant or refractory ovarian cancer: Participants must have received or after at least 1 platinum-based therapy.
Other solid tumors (gastric cancer, CRC, esophageal and cholangiocarcinoma): Participants must have received greater than or equal to (≥)1 prior line of systemic therapy for advanced or metastatic disease; including prior line(s) in combination with immunotherapy or vascular endothelial growth factor inhibitor.
Participants must have advanced or metastatic solid tumors and have received ≥1 prior line of therapy.
Must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.
Measured creatinine clearance ≥60 milliliters per minute (mL/min)

Exclusion Criteria

Have known active central nervous system (CNS) metastases or carcinomatous meningitis.
Have significant cardiovascular disease
Have prolongation of the corrected QTcF \>470 milliseconds (msec) during screening. QTcF is calculated using Fridericia's Formula: QTcF = QT/(RR0.33)
Have evidence of ongoing and untreated urinary tract obstruction
Had previous hemi- or total-body radiation.
Had previous adoptive T-cell therapy (e.g., chimeric antigen receptor T-cell \[CAR-T therapy, T-cell receptor \[TCR\] therapy, etc.)
Unable to lie flat during, or otherwise tolerate, single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT) or magnetic resonance imaging (MRI).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Newport Beach?

Yes, this clinical trial (NCT07213791) has an active research site in Newport Beach, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ovarian Neoplasms Treatment Options in Newport Beach, CA

If you're searching for ovarian neoplasms treatment options in Newport Beach, CA, this clinical trial (NCT07213791) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Newport Beach research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ovarian neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ovarian neoplasms clinical trials near you to find additional studies recruiting in your area.

More Ovarian Cancer Trials in Newport Beach, CA

See all ovarian cancer clinical trials recruiting in Newport Beach — not just this study.

Browse Ovarian Cancer Trials in Newport Beach →

Browse More Trials by Condition

Ovarian Cancer TrialsMultiple Sclerosis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Newport Beach?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Newport Beach, CA